Sfoglia per AUTORE
MINA R
Collezione AO Cuneo

  

Items : 8

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino
AO Cuneo

Boccadoro M; Gay F; Ballanti S; Belotti A; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Grasso M; Zamagni E; Fioritoni F; Cea M; Pescosta N; Vincelli ID; Ronconi S; Pavone V; Capra A; Oddolo D; de Fabritiis P; Palmas A; Mina R; Paris L; Aquino S; Gamberi B; Rota-Scalabrini D; Musto P;

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.

2023
ASL Torino 5
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara

Coviello E; Cilloni D; Passamonti F; Corradini P; Bertù L; Guidetti A; Visco C; Pagano L; Gherlinzoni F; Galimberti S; Tisi MC; Cudillo L; Gentile M; Mohamed S; Visani G; Federici AB; Della Porta MG; Mauro FR; Gambacorti-Passerini C; Massaia M; Bocchia M; Scattolin A; Billio A; Marchesi F; Trentin L; Cattaneo C; Derenzini E; Fracchiolla NS; Romano A; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AOU Alessandria

Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Musto P; Coviello E; Romano A; Passamonti F; Corradini P; Krampera M; Tosi P; Lanza F; Candoni A; Selleri C; Conconi A; Visani G; Vallisa D; Venditti A; Gambacorti-Passerini C; Rigacci L; La Barbera EO; Corso A; Armiento D; Cilloni D; Cardinali V; Galimberti S; Bocchia M; et alii...

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
ASL Torino 5
AOU Città della Salute di Torino

Passamonti F; Arcaini L; Bruno R; Antonio Grossi P; Corradini P; Pagano L; Busca A; Giuliani N; Luppi M; Tosi P; Mohamed S; Corso A; Rigacci L; Giovanni Della Porta M; Lanza F; Venditti A; Massimo Lemoli R; Billio A; Gentile M; Falini B; Turrini M; Tafuri A; Morotti A; Chiara Tisi M; Galimberti S; Coviello E; Trentin L; Cuneo A; Bocchia M; et alii...

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. in British journal of haematology / Br J Haematol. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16.

2021
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Bertù L; Pagano L; Corradini P; Musto P; Petrucci L; Zaja F; Grossi PA; Visani G; Lanza F; Cattaneo C; Mina R; La Barbera EO; Cardinali V; Galimberti S; Luppi M; Armiento D; Candoni A; Krampera M; Fracchiolla N; Bocchia M; Marchesi F; Tafuri A; Pinto A; Arcaini L; Ladetto M; Massaia M; Busca A; Venditti A; Romano I; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Bonello F; Monaco F; Corradini P; Boccadoro M; Offidani M; Mina R; Ballanti S; De Sabbata G; Aquino S; De Paoli L; Grasso M; Cellini C; Paris L; Belotti A; Tacchetti P; Cea M; Zambello R; Musolino C; Patriarca F; Rota-Scalabrini D; Capra A; Pescosta N; Petrucci MT; Ciccone G; Bringhen S; Liberati AM; Falcone AP; Larocca A;

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Biella
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Alessandria

Sonneveld P; Boccadoro M; Larocca A; Musto P; Romano A; Ria R; Giuliani N; Offidani M; Liberati AM; Marchetti M; Mosca-Siez ML; de Fabritiis P; Ballanti S; Monaco F; Gobbi M; Cellini C; Grasso M; Ronconi S; Pescosta N; Petrucci MT; Capra A; Zambello R; Mina R; Di Lullo G; Belotti A;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...